Literature DB >> 9357387

Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes.

R F Frye1, G R Matzke, A Adedoyin, J A Porter, R A Branch.   

Abstract

OBJECTIVES: To determine whether the probe drugs caffeine, chlorzoxazone, dapsone, debrisoquin (INN, debrisoquine), and mephenytoin can be simultaneously administered as a metabolic cocktail to estimate in vivo cytochrome P450 (CYP) and N-acetyltransferase enzyme activities.
METHODS: Fourteen healthy nonsmoking male volunteers (mean age +/- SD, 21.6 +/- 2.2 years) received 100 mg caffeine, 250 mg chlorzoxazone, 100 mg dapsone, 10 mg debrisoquin, and 100 mg mephenytoin individually and in four and five-drug combinations in a randomized manner using a 7 x 7 Latin square. Each drug or drug combination was given orally after an overnight fast, with a minimum 1-week washout between administrations. In each session, urine was collected from 0 to 8 hours and plasma was obtained at 4 and 8 hours after drug administration. Plasma and metabolite concentrations were used to estimate phenotypic trait measures for the efficiency of each drug's metabolism.
RESULTS: The phenotypic indexes determined for caffeine, chlorzoxazone, dapsone, debrisoquin, and mephenytoin were not significantly different when given alone than when given in combination. The median percentage change of the trait measures observed during administration of all five compounds compared with individual administration ranged from -10.7% for the 6-hydroxychlorzoxazone to chlorzoxazone plasma ratio to +2.2% for the debrisoquin recovery ratio.
CONCLUSIONS: The results of this study show that caffeine, chlorzoxazone, dapsone, debrisoquin, and mephenytoin in low doses can be simultaneously administered without metabolic interaction. This cocktail approach can thus simultaneously provide independent in vivo phenotypic measures for multiple CYP enzymes and N-acetyltransferase.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9357387     DOI: 10.1016/S0009-9236(97)90114-4

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  49 in total

1.  Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.

Authors:  P Damkier; L L Hansen; K Brosen
Journal:  Br J Clin Pharmacol       Date:  1999-12       Impact factor: 4.335

2.  Systemic uptake of miconazole during vaginal suppository use and effect on CYP1A2 and CYP3A4 associated enzyme activities in women.

Authors:  Mia Birkhøj Kjærstad; Flemming Nielsen; Lene Nøhr-Jensen; Stine Zwisler; Kim Brøsen; Helle Raun Andersen
Journal:  Eur J Clin Pharmacol       Date:  2010-10-06       Impact factor: 2.953

3.  Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1.

Authors:  G E Blakey; J A Lockton; J Perrett; P Norwood; M Russell; Z Aherne; J Plume
Journal:  Br J Clin Pharmacol       Date:  2004-02       Impact factor: 4.335

4.  Effects of multiple-dose pegylated interferon alfa-2b on the activity of drug-metabolizing enzymes in persons with chronic hepatitis C.

Authors:  Samir K Gupta; Karen Kolz; David L Cutler
Journal:  Eur J Clin Pharmacol       Date:  2010-12-16       Impact factor: 2.953

5.  Evaluation of the effect of multiple-dose administration of R411, a dual alpha4beta1-alpha4beta7 integrin antagonist on the major CYP isoform activities in healthy volunteers.

Authors:  Youssef Hijazi; Horst Welker; Albert E Dorr; Karl Frank; Louis M Renzetti; Indravadan Patel
Journal:  Eur J Clin Pharmacol       Date:  2005-12-21       Impact factor: 2.953

6.  Altered cytochrome 2E1 and 3A P450-dependent drug metabolism in advanced ovarian cancer correlates to tumour-associated inflammation.

Authors:  Sebastian Trousil; Patrizia Lee; Robert J Edwards; Lynn Maslen; Jingky P Lozan-Kuehne; Ramya Ramaswami; Eric O Aboagye; Stephen Clarke; Christopher Liddle; Rohini Sharma
Journal:  Br J Pharmacol       Date:  2019-08-05       Impact factor: 8.739

7.  Simultaneous phenotyping of CYP2E1 and CYP3A using oral chlorzoxazone and midazolam microdoses.

Authors:  Nicolas Hohmann; Antje Blank; Jürgen Burhenne; Yosuke Suzuki; Gerd Mikus; Walter E Haefeli
Journal:  Br J Clin Pharmacol       Date:  2019-08-09       Impact factor: 4.335

8.  Clinical use of pharmacogenomic tests in 2009.

Authors:  Leslie J Sheffield; Hazel E Phillimore
Journal:  Clin Biochem Rev       Date:  2009-05

9.  The basel cocktail for simultaneous phenotyping of human cytochrome P450 isoforms in plasma, saliva and dried blood spots.

Authors:  Massimiliano Donzelli; Adrian Derungs; Maria-Giovanna Serratore; Christoph Noppen; Lana Nezic; Stephan Krähenbühl; Manuel Haschke
Journal:  Clin Pharmacokinet       Date:  2014-03       Impact factor: 6.447

10.  A convenient five-drug cocktail for the assessment of major drug metabolizing enzymes: a pilot study.

Authors:  Ashish Sharma; Sylvie Pilote; Pierre M Bélanger; Marie Arsenault; Bettina A Hamelin
Journal:  Br J Clin Pharmacol       Date:  2004-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.